![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/index-pharmaceuticals-announces-expected-cash-balance-per-march-31-2024-302039363.html
https://www.prnewswire.com/news-releases/index-pharmaceuticals-discontinues-cobitolimod-phase-iii-program-301995261.html
https://www.prnewswire.com/news-releases/index-pharmaceuticals-has-been-granted-a-new-patent-for-cobitolimod-in-south-korea-301963166.html
https://www.prnewswire.com/news-releases/index-pharmaceuticals-announces-that-all-patients-needed-for-the-cobitolimod-dose-selection-milestone-have-completed-induction-study-1-of-the-phase-iii-program-conclude-301953209.html
https://www.prnewswire.com/news-releases/index-pharmaceuticals-is-attending-the-uegw-2023-congress-301948229.html
https://www.prnewswire.com/news-releases/positive-results-from-pk-study-with-cobitolimod-selected-as-one-of-the-best-abstracts-for-poster-presentation-at-uegw-index-pharmaceuticals-301906507.html
https://www.prnewswire.com/news-releases/index-pharmaceuticals-has-been-granted-a-new-patent-in-europe-for-the-commercial-formulation-of-cobitolimod-301891270.html
https://endpts.com/viatris-targets-ulcerative-colitis-in-japan-through-10m-agreement-with-index/
https://www.prnewswire.com/news-releases/index-pharmaceuticals-investor-call-at-1500-cet-on-june-1-301839020.html
https://www.prnewswire.com/news-releases/index-pharmaceuticals-announces-license-agreement-with-viatris-japan-to-develop-and-commercialize-cobitolimod-in-japan-301839003.html